Glenmark Life Sciences IPO Listing today, GMP indicated moderate listing gain
August 06, 2021 8:03 ISTGlenmark Life Sciences IPO Listing Date, Glenmark Life Sciences Share Price: Glenmark Life Sciences IPO GMP is currently at Rs 85.
Glenmark Life Sciences IPO Listing Date, Glenmark Life Sciences Share Price: Glenmark Life Sciences IPO GMP is currently at Rs 85.
Glenmark Life Sciences IPO Allotment status, Glenmark IPO GMP today: Glenmark Life Sciences IPO allotment status has been finalised. Glenmark IPO allotment status is available on KFintech's website. Glenmark Life Sciences shares will be listed on the BSE and NSE on August 6.
Glenmark Life Sciences IPO Allotment, Glenmark Life Sciences IPO GMP Latest: Glenmark Life Sciences IPO allotment status will be available on the website of KFintech.
Glenmark IPO Allotment Date, Glenmark Life Sciences IPO GMP: Glenmark Life Sciences is a subsidiary of Glenmark Pharmaceuticals. Glenmark Life Sciences IPO listing date is August 6.
The public issue will have a fresh issue of equity shares worth up to Rs 1,060 crore and sale of up to 63 lakh equity shares by Glenmark Pharma.
Banzel tablets are used in combination with other medications to treat children with Lennox-Gastaut syndrome, a severe form of childhood epilepsy that also causes developmental and behavior problems
Shares of Glenmark Pharmaceuticals were trading 2.41 per cent higher at Rs 499.10 apiece on the BSE.
Drug major Glenmark Pharma on Monday said it has received tentative approval from the US health regulator for anticoagulant Dabigatran Etexilate capsules.
Drug major Glenmark Pharma on Wednesday said it has received final approval from the US health regulator for Tacrolimus capsules, used as immuno-suppressant.
Glenmark Pharmaceuticals on Monday said it has received approval from the US health regulator to market Sirolimus tablets, an immunosuppressant, in the American market.
Glenmark Pharma on Wednesday announced the launch of its generic version of Nintedanib (NINDANIB), used for the treatment of pulmonary fibrosis, in India.
Shares of Glenmark Pharmaceuticals on Monday rallied 27 per cent after the company said it has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19.
Glenmark Pharmaceuticals on Monday received final approval from the US health regulator USFDA for its generic version of AstraZeneca's Xylocaine ointment. The approval given by the US Food & Drug Administration (USFDA) to Glenmark Pharmaceuticals
New Delhi, Dec 24: Glenmark Pharmaceuticals rose by 4 per cent to hit its 52-week high of Rs 519.70 following the company's collaboration with Forest Laboratories for worldwide collaboration on Novel Agents to treat chronic
Top News
Latest News
